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Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients
(REGENESIS-LED trial)
Steven C. Cramer1*, Michael D. Hill2, for the REGENESIS-LED Investigators
Introduction Preclinical studies suggest that growth factors in
the early days after stroke improve final outcome. A prior
study found three doses of human choriogonadotropin alfa
followed by three doses of erythropoietin to be safe after
stroke in humans. A proof of concept trial (REGENESIS) was
initiated but placed on regulatory hold during review of an
erythropoietin neuroprotective trial. Due to financial con-
straints, the trial was largely moved to India, using lower
erythropoietin doses, as the REGENESIS-LED trial.
Methods Entry criteria included National Institutes of Health
Stroke Scale 8–20, supratentorial ischemic stroke, and 24–48 h
poststroke at start of therapy. Patients were randomized to
three QOD doses of subcutaneous human choriogonadotropin
alfa followed by three QD doses of intravenous erythropoietin
(three escalating dose cohorts, 4000–20 000 IU/dose) vs.
placebo. Primary outcomes were safety and neurological
recovery.
Results The study was halted early by the sponsor after 96
enrollees. There was no significant difference across treatment
groups in the proportion of patients experiencing death,
serious adverse events, or any adverse event. There was no
significant difference in National Institutes of Health Stroke
Scale score change from baseline to Day 90 between placebo
and active treatment, whether active cohorts were analyzed
together or separately, and no exploratory secondary measure
of neurological recovery showed a significant difference
between groups.
Discussion Administration of human choriogonadotropin alfa
followed by erythropoietin is safe after a new ischemic stroke.
At the doses studied, placebo and active groups did not differ
significantly in neurological recovery. Study limitations, such
as the use of multiple assessors, differences in rehabilitation
care, and being underpowered to show efficacy, are discussed.
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Introduction
Increasing evidence suggests the potential to favorably modify
outcome after stroke with restorative therapies (1–3). The goals of
restorative interventions are to amplify innate processes of neural
repair, and so differ from reperfusion and neuroprotection
strategies after stroke. Preclinical work suggests the value of
growth factors (4,5), in particular, that sequential administration
of growth factors results in amplified endogenous neurogenesis
after experimental stroke (6–8). For example, in preclinical rodent
stroke studies, sequential administration of human choriogo-
nadotropin alfa (hCG), which stimulates endogenous neural
stem cell proliferation, followed by erythropoietin (EPO), which
promotes neural stem cell survival and differentiation to a neu-
ronal fate, results in improved neurological function (8). The
BETAS trial, a Phase IIa safety study, translated this approach to
human subjects, using subcutaneous (SQ) hCG 10 000 IU fol-
lowed by intravenous (IV) EPO 30 000 IU, and found no safety
concerns when initiated an average of 40 h postonset in 15 human
subjects with ischemic stroke (9).
In response to these findings, the REGENESIS trial (clinicaltri-
als.gov ID NCT00663416 and NCT00715364) was designed as a
Phase IIb proof of concept trial aimed at testing the effect of
NTx®-265 (385 μg SQ hCG on Days 1, 3, and 5 of study partici-
pation, then 30 000 IU IV EPO on Days 7, 8, and 9), in patients
suffering acute stroke, at 17 North American sites. This trial ran-
domized patients 1:1 with National Institutes of Health Stroke
Scale (NIHSS) score 6–24 who were 24–48 h after acute ischemic
stroke to either placebo or to NTx®-265. The trial was put on hold
on September 15, 2008 by the Food and Drug Administration
(FDA) (United States) and Health Canada (Canada) due to con-
cerns related to a separate acute stroke trial (10) that examined
the neuroprotective effects of multiple doses of high-dose EPO
(40 000 IU) started within six-hours of onset of ischemic stroke.
In that neuroprotective trial (10), EPO was associated with a
significant increase in mortality relative to placebo when
co-administered with tissue plasminogen activator, with 63% of
enrollees in that study having received thrombolytic therapy. At
the time that the REGENESIS trial was put on hold, seven patients
had been randomized, two of whom received active treatment,
and all of whom suffered no serious adverse events related to
study drug.
Subsequently, in response to a comprehensive review of NTx-
265® clinical safety data by the US FDA, the REGENESIS trial was
modified to be a dose-ranging safety study to characterize the
safety of lower EPO doses of ‘REGENESIS-LED’. Sites were initi-
ated in the United States, Canada, and India. The objectives of the
REGENESIS-LED trial were to assess the effect of sequential hCG
and EPO, relative to placebo, in patients with a new ischemic
stroke, with respect to (1) safety and tolerability, and (2) neuro-
logical recovery, measured as change in NIHSS score from base-
line to Day 90. The current report describes the results from the
REGENESIS-LED trial.
Correspondence: Steven C. Cramer*, Departments of Neurology and
Anatomy & Neurobiology, University of California, Irvine Medical
Center, 200 S. Manchester Ave., Suite 206, Orange, CA 92868, USA.
E-mail: scramer@uci.edu
1Departments of Neurology and Anatomy & Neurobiology, University of
California, Irvine, CA, USA
2Department of Neurology, University of Calgary, Calgary, AB, Canada
Received: 22 June 2013; Accepted: 14 October 2013; Published online
03 March 2014
Conflict of interest: Steve Cramer has served as a paid consultant to
Stem Cell Therapeutics, GlaxoSmithKline, Microtransponder, and Pfizer/
Cogstate.
Clinicaltrials.gov ID # NCT00938314
Funding: This study was funded by Stem Cell Therapeutics.
DOI: 10.1111/ijs.12260
Research
© 2014 The Authors.
International Journal of Stroke © 2014 World Stroke Organization
Vol 9, April 2014, 321–327 321
Methods
Study design
The REGENESIS-LED trial was a randomized, double-blind,
placebo-controlled, dose escalation, multicenter, international
study. The protocol was very similar in design to the BETAS trial
(9), which examined the same sequential drug regimen but which
used a higher and fixed dose of EPO compared with REGENESIS-
LED. Patients received study drug/placebo on Study Days 1, 3, and
5 (placebo or SQ hCG) and on Study Days 7, 8, and 9 (placebo or
IV EPO), followed by 81 days of observation, for total study
duration of 90 days. This study used commercially available drug
products: human choriogonadotropin alfa (hCG) was Ovidrel™
in North America and Ovitrelle™ in India, and EPO was
EPOGEN™ in the United States and EPREX™ in Canada and
India. All study procedures were approved by local human sub-
jects committees and conducted in accordance with Good Clini-
cal Practices guidelines. Prior to study initiation, an Investigators’
Meeting was conducted to provide information and training to all
site and sponsor staff, including training in the performance of
each outcome measure.
Enrollment of 128 patients was planned in three cohorts (32 in
Cohort 1, 32 in Cohort 2, and 64 in Cohort 3). In each cohort,
patients were randomized through a central interactive web
response system in a 3 : 1 ratio of active (SQ hCG followed by IV
EPO) or placebo (SQ saline followed by IV saline). In the active
arm, the dose of hCG was fixed at 10 000 IU (385 μg) per dose,
and the dose of EPO increased by 8000 IU per cohort beginning at
4000 IU – Cohort 1: 4000 IU EPO/dose; Cohort 2: 12 000 IU
EPO/dose; Cohort 3: 20 000 IU EPO/dose. Entry criteria are listed
in Table 1.
Study assessments
Patients underwent a screening visit and provided informed
consent within 48 h of stroke onset. Patients were serially evalu-
ated clinically and with laboratory testing throughout the drug-
dosing period, and at Days 16, 30, and 90 (see Supporting
Information Table S1), including modality-specific outcome
measures such as the Action Research Arm Test (ARAT). On Day
30 all patients underwent bilateral leg venous ultrasound to
screen for possible asymptomatic deep venous thrombosis.
Outcome measures
The primary outcome was safety, which was assessed based on
mortality, adverse event reporting, and serial assessment of vital
signs and clinical laboratory testing. A clinical monitor was
assigned to each study site. In addition, the study sponsor, Stem
Cell Therapeutics (SCT), monitored clinical trial sites in North
America, while Maya Clinicals, a contract research organization,
monitored sites in India. Safety was monitored on an ongoing
basis throughout the study by an independent data safety and
monitoring board (DSMB), which consisted of a chairperson
(physician), a statistician, a hematologist, and a stroke neurolo-
gist. Data were provided to the DSMB for each patient who died
or experienced a serious adverse event, as the event occurred. In
addition, safety data were provided to the DSMB, in aggregate,
for their review. The DSMB assessed safety prior to escalating to
the next dose cohort. The DSMB had the authority to halt
further enrollment if there were any safety concerns that needed
to be addressed, and to make recommendations to the study
that would ensure the safety of patients. The primary clinical
endpoint was the change in the NIHSS score from baseline to
Day 90.
Table 1 Entry and exclusion criteria
Entry criteria
Age 18–85 years
NIHSS score 8–20 when assessed 24–48 h after stroke onset
Stroke is ischemic in origin, supratentorial, and radiologically-confirmed via CT or MRI
Patient is 24–48 h from time of stroke onset at time of first dose of study drug administration
Reasonable expectation to be available to receive the full 9-day course of study drug and to be available for subsequent follow-up visits
Reasonable expectation that patient would receive standard of care poststroke physical, occupational, and speech therapy
Female patients must be either not of childbearing potential or agree to use nonhormonal forms of contraception throughout the study
Exclusion criteria
Patients presenting with lacunar, hemorrhagic, and/or brain stem stroke
Patients receiving thrombolytic treatment with tPA following the index stroke
Comatose or obtunded (NIHSS Q1A score must be <2)
Pregnancy, breastfeeding, or not using a highly effective method of birth control that would be maintained for the duration of the study
Blood hemoglobin > 16 g/dl (males) or >14 g/dl (females); or platelet count > 400 000/mm3
Advanced liver, kidney, cardiac, or pulmonary disease
Known and documented elevated prostate specific antigen levels
Known history of hypercoagulability
Expected survival < one-year
Allergy or other contraindication to either hCG or erythropoietin
A known diagnosis of cancer in the prior five-years (except nonmalignant skin cancer)
Patients with a pre-stroke modified Rankin Scale score (mRS) ≥ 2
Preexisting and active major psychiatric or other chronic neurological disease
Concurrent participation in another investigational study
CT, computed tomography; hCG, human choriogonadotropin alfa; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIHSS, National
Institutes of Health Stroke Scale; tPA, tissue plasminogen activator.
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Statistical methods
Sample size determination was based upon mortality as an
outcome and modeled using the 15 patients who received EPO
30 000 IU in the BETAS study (9) [of NTx®-265], among whom
entry criteria were very similar to the REGENESIS-LED study.
The posterior probability distribution around the true unknown
probability of death associated with NTx®-265, assuming a
uniform beta prior distribution as a starting point, is a beta bino-
mial with parameters alpha = 1 and beta = 16. Based on 1000
simulations of this posterior distribution (beta binomial with
alpha = 1 and beta = 16), the probability that the mortality rate is
less than 10% is 0·817 and the upper one-sided 95% interval
estimate of mortality is 16·6%. With a cohort size of at least 25
patients, if two or fewer deaths are observed, there is a probability
of at least 80% that the mortality rate is less than 10% in each
cohort.
Safety analyses were performed on all randomized patients
who received any amount of study medication, with patients
classified according to actual treatment received. Clinical neuro-
logical outcome analyses were conducted using a modified
intention-to-treat analysis set, defined as all randomized patients
who received at least one dose of study drug, with patients clas-
sified according to initial randomization group. A per-protocol
(PP) analysis set was also examined in secondary analyses, defined
as all randomized patients who received the full course of study
treatment, did not have a recurrent stroke, and had no major
protocol violations.
The primary neurological endpoint related to neurological
recovery, change in NIHSS score from baseline to Day 90, was
analyzed using an analysis of covariance, with treatment group as
a fixed effect, and with baseline NIHSS score and age used as
covariates. Primary analysis compared patients receiving placebo
with all patients in the three active treatment groups combined.
Outcomes for patients who did not complete the Day 90 assess-
ment were imputed based on the last available score carried
forward method; patients missing all postbaseline data had a
change score of 0 imputed. A secondary analysis using the same
model explored the dose response using a closed testing proce-
dure to compare placebo with each of the individual active dose
groups. Clinical operations personnel from SCT and Maya Clini-
cals remained blinded to data analyses until the database was
locked. All analyses were conducted using SAS v9·2 (SAS Institute
Inc., Cary, NC, USA), with two-sided alpha = 0·05, and no cor-
rections were made for multiplicity.
Results
Enrollees
Enrollment in the REGENESIS-LED study occurred between
August 2009 and March 2010 (Fig. 1). Enrollment was terminated
by the sponsor early, after 96 patients, due to slow enrollment, and
implemented by halving the size of Cohort 3 to 32 patients. Of the
96 enrollees, 93 were from India and 3 were from North America.
Baseline features are presented in Table 2. and were similar across
treatment groups. Overall, strokes were moderate in severity at
baseline (Table 3).
All 96 enrollees were included in the safety analyses and in the
modified intention-to-treat population. The PP population was
88 patients, with 8 patients excluded (two placebo, two low-dose,
three medium-dose, and one in the high-dose group), including
one for incorrect dosing; this patient was randomized to the
placebo group, received placebo on Days 1, 3, and 5 as planned,
but mistakenly received high-dose EPO on Days 7, 8, and 9. This
patient was considered to be in the high-dose NTx®-265 group
for safety and PP analyses but the placebo group for the modified
intention-to-treat analyses. Protocol deviations were noted in 52
patients (54·2%), were mainly related to timing of procedures
and assessments, and their rate did not significantly differ
between groups (45·8% placebo group, 54·2% low-dose group,
70·8% medium-dose group, and 45·8% high-dose group;
P > 0·25).
All 96 randomized patients received at least one dose of study
medication. Administration of all study drug doses was com-
pleted in 88 (91·7%) enrollees, and this did not differ significantly
between study groups.
Of these 96, 82% completed the study through Day 90, 19
(79%) in the placebo group and 60 (83%) in the active therapy
groups. Reasons for noncompletion included death in eight
(8·3%), withdrawal of consent in seven (7·3%), and loss to
follow-up in two (2·1%) patients. The nine patients who specifi-
cally terminated before Day 90 due to adverse events were simi-
larly distributed across treatment groups, eight of whom died and
one of whom experienced pyrexia and withdrew from further
study participation.
Safety
There was no significant difference across treatment groups in
the proportion of patients experiencing death, any serious
adverse event, or any adverse event (Table 4). Patient classifica-
tion for safety analyses was 23 in the placebo group, 24 in low-
dose, 24 in medium-dose, and 25 in the high-dose group. A list
of all serious adverse events is presented in Supporting Infor-
mation Table S2. A total of 12 serious adverse events were
reported across 11 of the 96 patients (two placebo, three low-
dose, four medium-dose, and three high-dose group), the most
common of which were cardiac arrest (n = 6) and new stroke
(n = 4). None of these 12 were considered by the principal inves-
tigators or medical monitor to be possibly, probably, or defi-
nitely related to the study drug, and the DSMB did not identify
any safety issues precluding continued enrollment into the
study. This rate was not significantly different between groups
(P > 0·5, two-tailed Fisher’s exact test), whether active groups
were analyzed together or separately. Eight of these serious
adverse events were fatal, for a study mortality rate of 8·3%: one
in placebo, one in the low-dose, three in the medium-dose, and
three in the high-dose group. The mortality rate was not signifi-
cantly different between groups (P > 0·5) whether active groups
were analyzed together or separately. In the placebo group, a
50-year-old died from ventricular fibrillation on Study Day 6. In
the low-dose active group, a 78-year-old suffered respiratory dis-
tress followed by cardiac arrest on Day 6. In the medium-dose
active group, a 60-year-old experienced cardiorespiratory arrest
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on Day 3; an 83-year-old experienced sudden cardiac death on
Day 14; and a 70-year-old experienced sudden cardiac death
on Day 16. In the high-dose active group, a 68-year-old experi-
enced cardiorespiratory arrest on Day 31; a 62-year-old experi-
enced dyspnea then died on Day 41; and a 61-year-old
experienced cardiorespiratory arrest on Day 20.
A total of 84 patients (87·5%) received a venous duplex scan,
with only one patient (medium-dose group) found to have a deep
vein thrombosis, which was asymptomatic. No study patient
experienced a pulmonary embolism or myocardial infarction.
The rate of any adverse events was similar between treatment
groups, reported in 52·2% of placebo patients and 52·1% of active
group patients (45·8% of low-dose, 79·2% of medium-dose, and
32·0% of high-dose patients); this rate was not significantly dif-
ferent between groups. A list of all adverse events appears in
Supporting Information Table S3. Vital signs were similar across
the four groups, including blood pressure one-hour after EPO (or
after placebo) administration on Study Days 7, 8, and 9. Active
treatment was not associated with a significant difference as com-
pared with placebo in the evolution of any of the blood chemistry
measures (screening to Study Day 9) or hematological tests
(screening to Study Day 9, 30, or 90, including hemoglobin and
reticulocyte count). There were also no significant differences
between treatment groups in serum iron measures (screening to
Study Day 9 or 30, including iron, total iron binding capacity, and
ferritin). Serum concentrations of hCG and EPO were tested after
the third dose, and in each case drug levels corresponded to
expected ranges.
Neurological recovery
Of the 96 enrollees, serial NIHSS score assessments were per-
formed by multiple examiners over time for 30 (31%) patients
despite pretrial training to use a single examiner, with NIHSS
assessments being compliant (i.e., using the same examiner over
time) for 66 patients. Using the modified intention-to treat popu-
lation (Fig. 1, Table 3), there was no statistically significant differ-
ence in the change in NIHSS score from baseline to Day 90
between placebo and active treatment (P = 0·31). This remained
true when each of the three active groups was separately com-
pared with placebo (Table 3).
None of the exploratory secondary measures of neurological
recovery showed a significant difference between groups, includ-
ing the total NIHSS score, % modified Rankin Scale ≤ 2, and the
Barthel Index score, at Day 30 and at Day 90, whether active
groups were analyzed together or separately, for either the modi-
fied intention-to-treat population or the PP population. Sites
were inconsistent in measuring modality-specific outcome mea-
sures, for example, an ARAT score was provided in 23 (24% of
Fig. 1 CONSORT diagram. The number of subjects screened was not recorded in this trial. Values displayed are for the modified intention-to-treat
population. EPO, erythropoietin; hCG, human choriogonadotropin alfa.
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enrollees) at baseline and in 56 (58% of enrollees) at Study Day
90.
At least one 15-min session of post-troke occupational therapy
(OT) was provided to 23% of patients; physical therapy, to 81%;
and speech therapy, to 29%. Post hoc analysis indicated that
patients who received at least one session of OT during the study
(23% of enrollees, with eight in placebo, eight in low-dose, five in
medium-dose, and one in high-dose group) might have had
better neurological recovery with active treatment: in the low-
dose group, the change in NIHSS score from baseline to Day 90
was 4·0 points greater than with placebo (P = 0·05); and in the
medium-dose group, the change in NIHSS score was 4·9 points
greater than with placebo (P = 0·03).
Discussion
Preclinical studies suggest the utility of sequential growth factors
to improve behavioral outcome when administered subacutely
after stroke (4,6–8), and a study in 15 patients with stroke 24–48 h
prior found hCG followed by EPO to be safe (9). The current
report describes the REGENESIS-LED study, which found that
sequential administration of SQ hCG and IV EPO over nine-days
Table 2 Baseline characteristics and demographics
Active:
combined groups
Active: separate groups
Placebo
groupLow-dose Medium-dose High-dose
n 72 24 24 24 24
Age (years) 56·9 ± 12·3 57·4 ± 10·5 58·6 ± 13·3 54·8 ± 13·0 61·7 ± 12·4
Gender (M/F) 23/49 6/18 10/14 7/17 8/16
Race
Asian 70 24 22 24 23
White 2 0 2 0 1
History of
Hypertension 65·3% 66·7% 50% 79·2% 58·3%
Diabetes mellitus 36·1% 41·7% 33·3% 33·3% 37·5%
Atrial fibrillation 2·8% 4·2% 4·2% 0% 4·2%
Coronary artery disease 4·2% 4·2% 0% 8·3% 12·5%
Stroke 11·1% 12·5% 12·5% 8·3% 0%
Weight (kg) 65·4 ± 8·7 64·9 ± 5·8 66·0 ± 8·1 65·2 ± 11·4 65·1 ± 10·9
Height (cm) 164·2 ± 6·6 163·6 ± 5·7 164·6 ± 7·8 164·5 ± 6·5 161·1 ± 7·5
Tobacco use
Current/Past use 23 (31·9%) 8 (33·3%) 7 (29·2%) 8 (33·3%) 10 (41·7%)
Never 48 (66·7%) 16 (66·7%) 16 (66·7%) 16 (66·7%) 14 (58·3%)
Unknown 1 (1·4%) 0 (0%) 1 (4·2%) 0 (0%) 0 (0%)
Alcohol use
Current/Past use 16 (22·2%) 4 (16·7%) 7 (29·2%) 5 (20·8%) 6 (25·0%)
Never 55 (76·4%) 20 (83·3%) 16 (66·7%) 19 (79·2%) 18 (75·0%)
Unknown 1 (1·4%) 0 (0%) 1 (4·2%) 0 (0%) 0 (0%)
Time from stroke onset to initiation of study drug (hours) 38·4 ± 6·4 38·2 ± 6·4 40·9 ± 6·1 36·1 ± 6·1 37·9 ± 6·9
OCSP classification
TACS 24 (33·3%) 9 (37·5%) 9 (37·5%) 6 (25·0%) 7 (29·2%)
PACS 44 (61·1%) 14 (58·3%) 13 (54·2%) 17 (70·8%) 16 (66·7%)
POCS 4 (5·6%) 1 (4·2%) 2 (8·3%) 1 (4·2%) 1 (4·2%)
Values are for the modified intention-to-treat population and are mean ± SD or percentage.
PACS, partial anterior circulation syndrome; POCS, posterior circulation syndrome; TACS, total anterior circulation syndrome.
Table 3 NIHSS scores from baseline to day 90
Active: combined groups
Active: separate groups
Placebo groupLow-dose Medium-dose High-dose
n 72 24 24 24 24
Baseline 13 [10 to 15·75] 14 [11 to 16·75] 12 [10·25 to 14] 12 [9 to 14·5] 12 [10 to 14]
Day 90 5·5 [2·25 to 9·75] 7 [4 to 11] 5·5 [2 to 9] 3 [2 to 8·75] 2·5 [2 to 8·25]
Change, Baseline to Day 90 −8 [−9 to −3·25] −8 [−9·75 to 3·25] −7·5 [−10 to −1·5] −6 [−9 to −5] −8 [−10 to −5]
Values are for the modified intention-to-treat population and are median [IQR]. Baseline scores were obtained at Visit 1, that is, the first day of study
participation. The change in NIHSS score did not differ significantly between placebo and active groups, whether evaluating active groups combined
or separately.
NIHSS, National Institutes of Health Stroke Scale.
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beginning 24–48 h after stroke onset is safe but is not associated
with improved neurological recovery at Day 90.
Administration of hCG followed by EPO is safe in patients with
a new ischemic stroke, including the absence of adverse events
related to EPO dose. There were no clinically significant differ-
ences between groups over time across the serum chemistry, iron,
coagulation, or hematology parameters, including hemoglobin.
At the doses studied, including EPO up to 20 000 IU/dose,
placebo and active groups did not differ significantly in neuro-
logical recovery.
The study was, ultimately, underpowered to show efficacy. It
remains possible that there is a small effect of growth factor
administration on stroke outcome and we have made a type 2
error. Interestingly, post hoc subgroup analysis suggested a
potential benefit of active treatment among the 23% of patients
who received poststroke OT, although this was an exploratory
observation. There were several observations in trial conduct that
may serve as future learning points for the studies in this area.
The first pertains to the potential impact of using multiple
patient assessors over time. Stroke scales do not have perfect
reproducibility. In the current trial, multiple raters assessed
patients at the various time-points throughout the course of
patient treatment. This may have substantially increased noise as
compared with use of a single rater over time. Second, the choice
of EPO dosing was affected by concerns about an unrelated neu-
roprotective study (10), and it remains possible that this reduc-
tion in dose substantially attenuated any possible biological
effect. The effect of this reduction was that the dose of EPO
studied in the REGENESIS-LED study was lower than the
equivalent dose used in rodent models, and so we were unable to
conform to the STAIR criteria and administer drug in humans at
similar dose levels to that used in preclinical models. Third, the
type and availability of rehabilitation care that was available in
India, where most study patients were enrolled, is substantially
different from what is available in North America. Abundant evi-
dence suggests that the brain plasticity induced by a restorative
therapy after stroke is experience dependent (11–13) – the favor-
able milieu produced by a restorative therapy has maximum
impact when it is shaped by behavioral experience, just as during
normal brain development (14). We would predict a priori that
consistent provision of physical and occupational therapy for
several weeks after stroke would interact with any therapy
designed to enhance neurogenesis.
Overall, hCG followed by EPO was not effective in promoting
neurological recovery after stroke, in the dosing paradigm and
stroke care settings studied here. The concept of induced stimu-
lation of neurogenesis as a treatment paradigm for stroke remains
to be proven.
Study sites
Steven C. Cramer – co-Primary Investigator.
Michael D. Hill – co-Primary Investigator.
India
Mathew Alexander, Christian Medical College Hospital, Vellore,
Tamilnadu; Subhashini Prabhakar, Apollo Hospitals, Hyderabad,
Andhra Pradesh; Puneet Agarwal, Max Super Speciality Hospital,
New Delhi; PN Sylaja, Ananthapuri Hospitals and Research Insti-
tute, Thiruvanthapuram, Kerala; Chandra Sekhar Reddy, Krishna
Institute of Medical Sciences, Hyderabad, Andhra Pradesh; JMK
Murthy, Care Hospital, Hyderabad, Andhra Pradesh; Jayaraj
Pandian, Christian Medical College and Hospital, Ludhiana,
Punjab; Jayanta Roy, Apollo Gleneagles Hospitals, Kolkata, West
Bengal; Dr.BS Keshava, JSS Medical College & Hospital, Banga-
lore, Karnataka; Srinivasa Rangasetty, MS Ramaiah Memorial
Hospital, Bangalore, Karnataka; Vikram Sharma, St. Theresa’s
General Hospital, Hyderabad, Andhra Pradesh; Vijaya Pami-
dimukkala, Lalitha Super Specialities Hospital Pvt Ltd, Guntur
Hyderabad, AP; Suresh Kumar, Vijaya Health Center, Chennai,
Tamildadu; E Srikantha Reddy, Kamineni Hospitals, Hyderabad,
Andhra Pradesh; Bhaskar Rao, Mediciti Hospital, Hyderabad,
Andhra Pradesh; Umesh Tukaram, Owaisi Hospital and Research
Center, Hyderabad, Andhra Pradesh; Anthati S Keerthi, DBR&SK
Superspeciality Hospital, Tirupati, Andhra Pradesh; Chalasani
Pramod, Latha Superspecialities Hospital, Vijayawada, Andhra
Pradesh; Dr.VVVB Choudary, Suraksha Neuro Centre,
Vijayawada, Andhra Pradesh; G Kishore Babu, Care Hospital,
Vishakapatnam, Andhra Pradesh; B Vengamma, Sri Venkateswara
Institute of Medical Sciences, Tirupati, Andhra Pradesh
Canada
Michael D. Hill, Foothills Hospital, Calgary, AB; Stephen Phillips,
Queen Elizabeth II Health Sciences Centre, Halifax, NS; Jeanne
Teitelbaum, Montreal Neurological Institute, Montreal, QC;
Table 4 Safety outcomes
Active: combined groups
Active: separate groups
Placebo groupLow-dose Medium-dose High-dose
n 73 24 24 25 23
Serious adverse events 10 3 4 3 2
Fatalities 7 1 3 3 1
Any adverse event 38 11 19 8 12
Safety analyses were performed on all randomized patients who received any amount of study medication, with patients classified according to actual
treatment received. Any adverse event includes serious adverse events, and serious adverse events include fatalities. There were no significant
differences across treatment groups in the proportion of patients experiencing a serious adverse event, fatality, or any adverse event.
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David Gladstone, Sunnybrook Health Science Center, Toronto,
ON
United States
Steven C. Cramer, University of California, Irvine Medical Center.
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